Here we used the MEK1/2 inhibitor, Selumetinib (AZD6244, ARRY-142886) as a model therapeutic to test ex vivo treatment of fresh, colorectal tumour biopsies as a method to determine patient sensitivity to new therapies. This evidence concerns the gene MAP2K1 and colorectal neoplasm.